Oncotarget

Research Papers:

Germline HOXB13 p.Gly84Glu mutation and cancer susceptibility: a pooled analysis of 25 epidemiological studies with 145,257 participates

Qiliang Cai _, Xinpeng Wang, Xiaodong Li, Rui Gong, Xuemei Guo, Yang Tang, Kuo Yang, Yuanjie Niu and Yan Zhao

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:42312-42321. https://doi.org/10.18632/oncotarget.5994

Metrics: PDF 1414 views  |   HTML 2476 views  |   ?  


Abstract

Qiliang Cai1, Xinpeng Wang1, Xiaodong Li2, Rui Gong3, Xuemei Guo4, Yang Tang1, Kuo Yang1, Yuanjie Niu1, Yan Zhao5

1Department of Urology, Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin, 300211, China

2Department of Radiotherapy, the Second Hospital of Tianjin Medical University, Tianjin, 300211, China

3Pharmaceutical Department, the Second Hospital of Tianjin Medical University, Tianjin, 300211, China

4Library of Tianjin Medical University, Tianjin Medical University, Tianjin, 300070, China

5Tianjin Institute of infectious diseases, the Second Hospital of Tianjin Medical University, Tianjin, 300211, China

Correspondence to:

Yan Zhao, e-mail: [email protected]

Keywords: HOXB13 gene, rs138213197, genetic mutation, cancer, risk

Received: August 01, 2015     Accepted: October 05, 2015     Published: October 17, 2015

ABSTRACT

Numerous studies have investigated association between the germline HOXB13 p.Gly84Glu mutation and cancer risk. However, the results were inconsistent. Herein, we performed this meta-analysis to get a precise conclusion of the associations. A comprehensive literature search was conducted through Medline (mainly Pubmed), Embase, Cochrane Library databases. Crude odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated by STATA 12.1 software to evaluate the association of HOXB13 p.Gly84Glu mutation and cancer susceptibility. Then, 25 studies including 51,390 cases and 93,867 controls were included, and there was significant association between HOXB13 p.Gly84Glu mutation and overall cancer risk (OR = 2.872, 95% CI = 2.121–3.888, P < 0.001), particularly in prostate cancer (OR = 3.248, 95% CI = 2.313–4.560, P < 0.001), while no association was found in breast (OR = 1.424, 95% CI = 0.776–2.613, P = 0.253) and colorectal cancers (OR = 2.070, 95% CI = 0.485–8.841, P = 0.326). When we stratified analysis by ethnicity, significant association was found in Caucasians (OR = 2.673, 95%CI = 1.920–3.720, P < 0.001). Further well-designed with large samples and other various cancers should be performed to validate our results.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5994